Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 15/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 13/20 | 0.56 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.56 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.53 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401624 | 0.98 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL8141367 | 0.96 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL29018586 | 0.84 | POLB (0.56) | L3MBTL3L3MBTL1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL18241088 | 0.82 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3020425 | 0.82 | POLB (0.58) | L3MBTL3L3MBTL1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL29018588 | 0.82 | POLB (0.53) | L3MBTL3L3MBTL1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL29018568 | 0.81 | HRH3 (0.44) | L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL920191 | 0.81 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL6806463 | 0.81 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL30491041 | 0.81 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113773293-B | Chrysin derivative and preparation method thereof | 深圳枫语生物医药科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-113773293-A | Chrysin derivative and preparation method thereof | 深圳枫语生物医药科技有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-108484624-B | Irinotecan hydrochloride impurity and synthesis method and application thereof | 扬子江药业集团有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-108484624-A | A kind of irinotecan hydrochloride impurity and its synthetic method and application | 扬子江药业集团有限公司 | 2018-09-04 | — | — | CN | claimed |
| US-9765083-B2 | Method for the synthesis of irinotecan | SYNBIAS PHARMA AG (CH) | 2017-09-19 | — | — | US | claimed |
| CN-102260272-B | A kind of method preparing U 101440E | YANGTZE RIVER PHARMACEUTICAL CO., LTD. (CN) | 2016-01-13 | — | — | CN | claimed |
| EP-1846371-B1 | PROCESS FOR PRODUCING [1,4']BIPIPERIDINYL-1'-CARBONYL CHLORIDE OR HYDROCHLORIDE THEREOF | FERMION OY (FI) | 2013-07-31 | — | — | EP | claimed |
| EP-2189461-B1 | Crystalline irinotecan hydrochloride and methods for the preparation thereof | OLON SPA (IT) | 2013-04-03 | — | — | EP | claimed |
| US-8247426-B2 | Crystalline irinotecan hydrochloride and methods for its preparation | ANTIBIOTICOS S.P.A. (IT) | 2012-08-21 | — | — | US | claimed |
| US-20100179180-A1 | CRYSTALLINE IRINOTECAN HYDROCHLORIDE AND METHODS FOR ITS PREPARATION | ANTIBIOTICOS S.P.A. (IT) | 2010-07-15 | — | — | US | claimed |
| US-20070135471-A1 | METHODS FOR PREPARING IRINOTECAN | W. C. HERAEUS GMBH (DE) | 2007-06-14 | — | — | US | claimed |
| EP-1791846-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF IRINOTECAN HYDROCHLORIDE TRIHYDRATE | Shilpa Medicare Limited (IN) | 2007-06-06 | — | — | EP | claimed |
| US-20060199961-A1 | Method of manufacturing of 7-ethyl-10-[4-(1-piperidino)-1- piperidino]- carbonyloxy- camptothecin | PLIVA - LACHEMA A.S., V LIKVIDACI (CZ) | 2006-09-07 | — | — | US | claimed |
| WO-2006084940-A1 | PROCESS FOR PRODUCING [1,4'] BIPIPERIDINYL-1'-CARBONYL CHLORIDE OR HYDROCHLORIDE THEREOF | FERMION OY (FI) | 2006-08-17 | — | — | WO | claimed |
| EP-1664054-A1 | METHOD OF MANUFACTURING OF 7-ETHYL-10-[4-(1-PIPERIDINO)-1-PIPERIDINO]-CARBONYLOXYCAMPTOTHECIN | Pliva-Lachema A.S. (CZ) | 2006-06-07 | — | — | EP | claimed |
| WO-2006016203-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF IRINOTECAN HYDROCHLORIDE TRIHYDRATE | SHILPA MEDICARE LIMITED (IN) | 2006-02-16 | — | — | WO | claimed |
| WO-2005019223-A1 | METHOD OF MANUFACTURING OF 7-ETHYL-10-[4-(1-PIPERIDINO)-1- PIPERIDINO]- CARBONYLOXYCAMPTOTHECIN | PLIVA-LACHEMA A.S. (CZ) | 2005-03-03 | — | — | WO | claimed |
| EP-0976733-B1 | PROCESS FOR PRODUCING 1-CHLOROCARBONYL-4-PIPERIDINOPIPERIDINE OR HYDROCHLORIDE THEREOF | YAKULT HONSHA KK (JP) | 2003-02-12 | — | — | EP | claimed |
| US-6147215-A | Process for producing 1-chlorocarbonyl-4-piperidinopiperidine or hydrochloride thereof | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2000-11-14 | — | — | US | claimed |
| EP-0976733-A1 | PROCESS FOR PRODUCING 1-CHLOROCARBONYL-4-PIPERIDINOPIPERIDINE OR HYDROCHLORIDE THEREOF | Kabushiki Kaisha Yakult Honsha (JP) | 2000-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179180-A1 | CRYSTALLINE IRINOTECAN HYDROCHLORIDE AND METHODS FOR ITS PREPARATION | TYMP, TOP2A, TOP2B | SIGMAR1 4135/4885L3MBTL3 4229/4885L3MBTL1 4003/4885 |
| US-20060199961-A1 | Method of manufacturing of 7-ethyl-10-[4-(1-piperidino)-1- piperidino]- carbonyloxy- camptothecin | TYMP, PAICS, TOP2A | SIGMAR1 2814/4885L3MBTL3 4622/4885L3MBTL1 4423/4885 |
| US-20070135471-A1 | METHODS FOR PREPARING IRINOTECAN | TYMP, PNP, PAICS | SIGMAR1 1462/4885L3MBTL3 4389/4885L3MBTL1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.